Biotech Cereno Scientific develops new treatments for cardiovascular disease, the most common cause of death worldwide. The company’s lead candidate CS1 targets the rare disease pulmonary arterial hypertension. CEO Sten R. Sörensen told BioStock more about Cereno Scientific’s lead candidate and work during BioStock Investor Meeting.
Watch the interview with Cereno Scientific’s CEO Sten R. Sörensen below.The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.